Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.

Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.

Mycophenolate mofetil helped reduce steroid use in treating a dog's autoimmune skin disease.

Rapamycin reduces age-related hearing cell loss in mice, but acarbose does not.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Oral calcitriol helped improve scleroderma and hair regrowth in a young woman.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Mesenchymal stem cell therapy shows promise for treating certain inflammatory skin diseases, but more research is needed.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

The mTOR signaling pathway might play a role in radiation dermatitis, but more research is needed.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

A patient with complete hair loss regrew all her hair using tofacitinib.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.

JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

A(1-7) treatment reduces symptoms of lupus in mice.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.